|
1
|
Buffa Filho W, Corsino J, Bolzani da SV,
Furlan M, Pereira AM and Franca SC: Quantitative determination for
cytotoxic Friedo-nor-oleanane derivatives from five morphological
types of Maytenus ilicifolia(Celastraceae) by reverse-phase
high-performance liquid chromatography. Phytochem Anal. 13:75–78.
2002.
|
|
2
|
Chang FR, Hayashi K, Chen IH, et al:
Antitumor agents. 228. five new agarofurans, Reissantins A-E, and
cytotoxic principles from Reissantia buchananii. J Nat Prod.
66:1416–1420. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sassa H, Kogure K, Takaishi Y and Terada
H: Structural basis of potent antiperoxidation activity of the
triterpene celastrol in mitochondria: effect of negative membrane
surface charge on lipid peroxidation. Free Radic Biol Med.
17:201–207. 1994. View Article : Google Scholar
|
|
4
|
Dirsch VM, Kiemer AK, Wagner H and Vollmar
AM: The triterpenoid quinonemethide pristimerin inhibits induction
of inducible nitric oxide synthase in murine macrophages. Eur J
Pharmacol. 336:211–217. 1997. View Article : Google Scholar
|
|
5
|
Figueiredo JN, Raz B and Sequin U: Novel
quinone methides from Salacia kraussii with in vitro
antimalarial activity. J Nat Prod. 61:718–723. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Costa PM, Ferreira PM, da Bolzani VS, et
al: Antiproliferative activity of pristimerin isolated from
Maytenus ilicifolia ( Celastraceae) in human HL-60 cells.
Toxicol In Vitro. 22:854–863. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang H, Landis-Piwowar KR, Lu D, et al:
Pristimerin induces apoptosis by targeting the proteasome in
prostate cancer cells. J Cell Biochem. 103:234–244. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yan YY, Bai JP, Xie Y, Yu JZ and Ma CG:
The triterpenoid pristimerin induces U87 glioma cell apoptosis
through reactive oxygen species-mediated mitochondrial dysfunction.
Oncol Lett. 5:242–248. 2013.PubMed/NCBI
|
|
9
|
Lee JS, Yoon IS, Lee MS, et al: Anticancer
activity of pristimerin in epidermal growth factor receptor
2-positive SKBR3 human breast cancer cells. Biol Pharm Bull.
36:316–325. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu CC, Chan ML, Chen WY, Tsai CY, Chang FR
and Wu YC: Pristimerin induces caspase-dependent apoptosis in
MDA-MB-231 cells via direct effects on mitochondria. Mol Cancer
Ther. 4:1277–1285. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lu Z, Jin Y, Chen C, Li J, Cao Q and Pan
J: Pristimerin induces apoptosis in imatinib-resistant chronic
myelogenous leukemia cells harboring T315I mutation by blocking
NF-kappaB signaling and depleting Bcr-Abl. Mol Cancer. 9:1122010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Byun JY, Kim MJ, Eum DY, et al: Reactive
oxygen species-dependent activation of Bax and poly(ADP-ribose)
polymerase-1 is required for mitochondrial cell death induced by
triterpenoid pristimerin in human cervical cancer cells. Mol
Pharmacol. 76:734–744. 2009. View Article : Google Scholar
|
|
13
|
Deeb D, Gao X, Liu YB, Pindolia K and
Gautam SC: Pristimerin, a quinonemethide triterpenoid, induces
apoptosis in pancreatic cancer cells through the inhibition of
pro-survival Akt/NF-κB/mTOR signaling proteins and anti-apoptotic
Bcl-2. Int J Oncol. 44:1707–1715. 2014.PubMed/NCBI
|
|
14
|
Mu XM, Shi W, Sun LX, et al: Pristimerin
inhibits breast cancer cell migration by up-regulating regulator of
G protein signaling 4 expression. Asian Pac J Cancer Prev.
13:1097–1104. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mu X, Shi W, Sun L, Li H, Jiang Z and
Zhang L: Pristimerin, a triterpenoid, inhibits tumor angiogenesis
by targeting VEGFR2 activation. Molecules. 17:6854–6868. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cooperberg MR, Park S and Carroll PR:
Prostate cancer 2004: insights from the national disease
registries. Oncology (Williston Park). 18:1239–1258.
2004.PubMed/NCBI
|
|
17
|
Prostate Cancer. National Cancer
Institute, U.S. National Institutes of Health Cancer.gov.
http:www.cancer.gov/cancer-topics/types/prostate.
Accessed Feb 7, 2014
|
|
18
|
Garnick MB: Hormonal therapy in the
management of prostate cancer: From Higgins to the present.
Urology. 49:5–15. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hanks GE: Long-term control of prostate
cancer with radiation. Urol Clin North Amer. 23:605–616. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu Y, Gao X, Deeb D, Ali S and Gautam SC:
Pristimerin induces apoptosis in prostate cancer cells by
down-regulating Bcl-2 through ROS-dependent ubiquitin-proteasomal
degradation pathway. J Carcinogen Mutagen. S6:005doi:
104172/2157–2518. S6–005. 2013.PubMed/NCBI
|
|
21
|
Wang Y, Zhou Y, Zhou H, et al: Pristimerin
causes G1 arrest, induces apoptosis, and enhances the
chemosensitivity to gemcitabine in pancreatic cancer cells. PLOS
One. 7:e438262012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chao DT and Korsmeyer SJ: BCL-2 family:
regulators of cell death. Annu Rev Immunol. 16:395–419. 1998.
View Article : Google Scholar
|
|
23
|
Green DR and Reed JC: Mitochondria and
apoptosis. Science. 281:1309–1312. 1998. View Article : Google Scholar
|
|
24
|
Deveraux QL and Reed JC: IAP family
proteins - suppressors of apoptosis. Genes Dev. 13:239–252. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tamm I, Wang Y, Sausville E, Scudiero DA,
Vigna N, Oltersdorf T and Reed JC: IAP-family protein survivin
inhibits caspase activity and apoptosis induced by Fas (CD95), Bax,
caspases, and anticancer drugs. Cancer Res. 58:5315–5320.
1998.PubMed/NCBI
|
|
26
|
Zhao J, Tenev T, Martins LM, Downward J
and Lemoine NR: The ubiquitin-proteasome pathway regulates survivin
degradation in a cell cycle-dependent manner. J Cell Sci.
113:4363–4371. 2000.PubMed/NCBI
|
|
27
|
Li F1, Ambrosini G, Chu EY, Plescia J,
Tognin S, Marchisio PC and Altieri DC: Control of apoptosis and
mitotic spindle checkpoint by surviving. Nature. 396:580–584. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Koepp DM, Harper JW and Elledge SJ: How
the cyclin became a cyclin: regulated proteolysis in the cell
cycle. Cell. 97:431–434. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Aberle H, Bauer A, Stappert J, Kispert A
and Kemler R: beta-catenin is a target for the ubiquitin-proteasome
pathway. EMBO J. 16:3797–3804. 1997. View Article : Google Scholar : PubMed/NCBI
|
